Search

Innate Pharma SA

Lezárt

1.854 3

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

1.8439999999999999

Maximum

1.8559999999999999

Fő mutatók

By Trading Economics

Bevétel

3.4M

-21M

Értékesítés

531K

4.9M

Profit margin

-439.177

Munkavállalók

174

EBITDA

-2M

-25M

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

+20.41% upside

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

13M

170M

Előző nyitás

-1.15

Előző zárás

1.854

Technikai pontszám

By Trading Central

Bizalom

Weak Bullish Evidence

Innate Pharma SA Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2025. okt. 24. 18:41 UTC

Eredményjelentés

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

2025. okt. 24. 18:31 UTC

Eredményjelentés

Correction to Procter & Gamble to Focus on Innovation

2025. okt. 24. 16:25 UTC

Fő piaci mozgatók

Obook Shares Rise, Company Secures New Money Transmitter Licenses

2025. okt. 24. 21:24 UTC

Piaci beszéd

Global Forex and Fixed Income Roundup: Market Talk

2025. okt. 24. 21:24 UTC

Piaci beszéd

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

2025. okt. 24. 21:07 UTC

Eredményjelentés

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

2025. okt. 24. 20:58 UTC

Eredményjelentés

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

2025. okt. 24. 20:50 UTC

Piaci beszéd

Financial Services Roundup: Market Talk

2025. okt. 24. 20:40 UTC

Eredményjelentés

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

2025. okt. 24. 20:24 UTC

Eredményjelentés

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025. okt. 24. 20:23 UTC

Eredményjelentés

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025. okt. 24. 20:13 UTC

Eredményjelentés

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. okt. 24. 20:07 UTC

Piaci beszéd

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

2025. okt. 24. 19:40 UTC

Piaci beszéd

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

2025. okt. 24. 19:35 UTC

Piaci beszéd

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

2025. okt. 24. 19:33 UTC

Eredményjelentés

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

2025. okt. 24. 19:29 UTC

Piaci beszéd

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

2025. okt. 24. 18:52 UTC

Eredményjelentés

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025. okt. 24. 18:41 UTC

Eredményjelentés

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025. okt. 24. 18:03 UTC

Eredményjelentés

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

2025. okt. 24. 18:02 UTC

Eredményjelentés

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

2025. okt. 24. 18:00 UTC

Piaci beszéd

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

2025. okt. 24. 16:57 UTC

Eredményjelentés

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

2025. okt. 24. 16:54 UTC

Piaci beszéd

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

2025. okt. 24. 16:44 UTC

Piaci beszéd
Eredményjelentés

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

2025. okt. 24. 16:39 UTC

Piaci beszéd
Eredményjelentés

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

2025. okt. 24. 16:33 UTC

Eredményjelentés

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. okt. 24. 16:23 UTC

Eredményjelentés

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025. okt. 24. 16:20 UTC

Piaci beszéd

Financial Services Roundup: Market Talk

2025. okt. 24. 16:07 UTC

Eredményjelentés

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Innate Pharma SA Előrejelzés

Célár

By TipRanks

20.41% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 2.228 EUR  20.41%

Magas 2.23 EUR

Alacsony 2.23 EUR

1 Wall Street elemző 12 hónapos célárain alapulva a(z)Innate Pharma SA termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

1 ratings

0

Vétel

1

Tartás

0

Eladás

Technikai pontszám

By Trading Central

1.91 / 2.1Támogatás & ellenállás

Rövid táv

Weak Bullish Evidence

Középtáv

Weak Bullish Evidence

Hosszú táv

Bullish Evidence

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
help-icon Live chat